Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAS 825

Next Previous
Drug Profile

MAS 825

Alternative Names: MAS-825

Latest Information Update: 17 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; The Hospital for Sick Children
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Bispecific antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors; Interleukin 18 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lymphoproliferative disorders
  • Phase II Coronary disorders; COVID-19 pneumonia; Enterocolitis; Hidradenitis suppurativa

Most Recent Events

  • 04 Nov 2024 Novartis completes a phase-II clinical trials in Coronary disorders in USA, Canada and Germany (SC) (NCT06097663)
  • 16 Feb 2024 Phase-II clinical trials in Coronary disorders in USA (SC)
  • 16 Feb 2024 Phase-II clinical trials in Coronary disorders in Canada (SC) (NCT06097663)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top